

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mediwelcome Healthcare Management & Technology Inc.

麥迪衛康健康醫療管理科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2159)

CHANGE OF COMPLIANCE ADVISER

The board of directors (the “**Board**”) of Mediwelcome Healthcare Management & Technology Inc. (the “**Company**”) announces that the Company and Shanxi Securities International Capital Limited (“**Shanxi Securities**”) have mutually agreed to terminate the compliance adviser agreement previously entered into between the Company and Shanxi Securities, with effect from 10 February 2022 due to commercial reasons (the “**Termination**”).

Shanxi Securities has confirmed that it has no disagreement with the Board. Each of the Board and Shanxi Securities confirms that, as at the date of this announcement, there are no other matters relating to the Termination that are required to be drawn to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Rainbow Capital (HK) Limited (“**Rainbow Capital**”) has been appointed as the new compliance adviser to the Company as required under Rule 3A.27 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) with effect from 10 February 2022 until (i) the date, pursuant to Rule 3A.19 of the Listing Rules, on which the Company complies with Rule 13.46 of the Listing Rules in respect of the financial results of the Company for the first full financial year commencing after the date of the Company’s initial listing (being the financial year ending 31 December 2022); or (ii) the compliance adviser agreement entered into between the Company and Rainbow Capital is terminated in accordance with its terms, whichever is earlier.

Rainbow Capital is a licensed corporation permitted to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

By order of the Board
Mediwelcome Healthcare Management & Technology Inc.
Shi Wei
Chairman and Executive Director

Hong Kong, 10 February 2022

As at the date of this announcement, the executive directors of the Company are Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang, Mr. Wang Wei and Mr. Sui Huijun; the non-executive directors of the Company are Ms. Zhang Yitao and Mr. Liu Xia; and the independent non-executive directors of the Company are Mr. Song Ruilin, Mr. Fei John Xiang, Mr. David Zheng Wang and Mr. Yang Xiaoxi.